David Dai

Stock Analyst at UBS

(0)
# 4963
Out of 5,331 analysts
23
Total ratings
16.67%
Success rate
-30.52%
Average return
20 Stocks
Name Action PT Current % Upside Ratings Updated
NUVL Nuvalent
Upgrades: Buy
100 100
77.59 28.88% 2 Mar 14, 2025
KURA Kura Oncology
Maintains: Buy
27 14
6.47 116.38% 2 Mar 6, 2025
IMCR Immunocore Hldgs
Initiates Coverage On: Sell
24
30.49 -21.29% 1 Oct 24, 2024
BPMC Blueprint Medicines
Initiates Coverage On: Neutral
88
104.69 -15.94% 1 Oct 24, 2024
CATX Perspective Therapeu...
Initiates Coverage On: Buy
20
2.56 681.25% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
35
11.27 210.56% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
72
44.26 62.68% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
69
32.94 109.47% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
50
21 138.1% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
17
3.52 382.95% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
30
8.81 240.52% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
60
29.05 106.54% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
37
13.73 169.48% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 2 Feb 24, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
28
0.66 4142.42% 1 Mar 31, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
40
12.2 227.87% 1 Mar 16, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
40
1.75 2185.71% 1 Feb 4, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
50
2.09 2292.34% 1 Nov 18, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Outperform
41 52
34.47 50.86% 1 Mar 17, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
41
n/a n/a 1 Apr 25, 2017